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Background:Efficacy and safety of alirocumabwere comparedwith ezetimibe inhypercholesterolemic patients at
moderate cardiovascular risk not receiving statins or other lipid-lowering therapy.
Methods: In a Phase 3, randomized, double-blind, double-dummy study (NCT01644474), patients (low-density
lipoprotein cholesterol [LDL-C] 100–190 mg/dL, 10-year risk of fatal cardiovascular events ≥1%–b5% [systemic
coronary risk estimation]) were randomized to ezetimibe 10 mg/day (n=51) or alirocumab 75 mg subcutane-
ously (via 1­mL autoinjector) every 2 weeks (Q2W) (n=52), with dose up-titrated to 150mg Q2W (also 1mL)
at week 12 if week 8 LDL-C was ≥70 mg/dL. Primary endpoint was mean LDL-C % change from baseline to
24 weeks, analyzed using all available data (intent-to-treat approach, ITT). Analyses using on-treatment LDL-C
values were also conducted.
Results: Mean (SD) baseline LDL-C levels were 141.1 (27.1) mg/dL (alirocumab) and 138.3 (24.5) mg/dL
(ezetimibe). The 24-week treatment period was completed by 85% of alirocumab and 86% of ezetimibe patients.
Least squares mean (SE) LDL-C reductions were 47 (3)% with alirocumab versus 16 (3)% with ezetimibe
(ITT; p b 0.0001) and 54 (2)% versus 17 (2)% (on-treatment; p b 0.0001). At week 12, before up-titration,
alirocumab 75 mg Q2W reduced LDL-C by 53 (2)% (on-treatment). Injection site reactions were infrequent
(b2% and b4% of alirocumab and ezetimibe patients, respectively).
Conclusions: Alirocumab demonstrated significantly greater LDL-C lowering versus ezetimibe after
24 weeks with the lower 75 mg Q2W dose sufficient to provide ≥50% LDL-C reduction in the majority of
the patients. Adverse events were comparable between groups.
© 2014 Sanofi and Regeneron. Published by Elsevier Ireland Ltd. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
Alirocumab (formerly SAR236553/REGN727), a fully human mono-
clonal antibody against proprotein convertase subtilisin/kexin 9
(PCSK9), significantly reduced low-density lipoprotein cholesterol
(LDL-C) when combined with other lipid-lowering therapies in three
Phase 2 studies of 8–12 weeks duration [1–3]. Alirocumab Phase 2 clin-
ical studies were all conductedwith patients on background statin ther-
apy [1–3]. Since statins increase PCSK9 levels, there is a need to also
study alirocumab as monotherapy (i.e. with no background lipid-
lowering therapies) to better understand the pharmacokinetics and
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treatment-emergent adverse events; TGs, triglycerides; ULN, upper limit of normal.
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pharmacodynamics of the drug, as well as its efficacy and safety, in pa-
tients not on statin therapy. Robust decreases in LDL-C were previously
reported in a small number of patients treated with alirocumab as
monotherapy [4].
We present data from the ODYSSEY MONO study, in the first report
from theODYSSEY program, a large series of Phase 3 studies designed to
provide a comprehensive assessment of the efficacy and safety of
alirocumab in a range of clinical settings and patient groups. The prima-
ry objective of this study was to evaluate the efficacy and safety of
alirocumabmonotherapy comparedwith ezetimibe in patientswith hy-
percholesterolemia and at moderate cardiovascular (CV) risk (i.e. a
10­year risk of fatal CV events ≥1% and b5%) [5], who were not receiv-
ing statin or other lipid-lowering therapy. Ezetimibe was utilized as the
comparator in this study as it is one of the options recommended for
treating patients with statin intolerance [6]. The study employed a pre-
viously unstudied alirocumab dose regimen of 75 mg every 2 weeks
(Q2W). The 75 mg Q2W dose was selected based on modeling data
from the alirocumab Phase 2 trials [7].
2. Methods
This was a Phase 3, randomized, double-blind, active-controlled, double-dummy
study (NCT01644474) conducted in eight centers in the USA, Belgium, Finland, and the
Netherlands, from July 2012 to July 2013. The study was performed in accordance with
the ethical principles in the Declaration of Helsinki, the International Conference on Har-
monization/Good Clinical Practice and appropriate regulatory requirements. The study
protocol was approved by the appropriate local independent ethics committees. Written,
informed consent was received from all patients before enrollment.
2.1. Patients
This study included male and female patients aged ≥18 years with a 10-year risk of
fatal CV events of≥1% and b5%, based on the European Systematic Coronary Risk Estima-
tion [5], a level of risk for which LDL-C lowering drug therapy can be considered [8].
Patients were not receiving statin or any other lipid-lowering therapy for at least
4 weeks prior to screening. Exclusion criteria are listed in Supplementary Table 1.
2.2. Study design
Patients were randomized (permuted-block design) in a 1:1 ratio to receive either
ezetimibe 10 mg/day orally plus alirocumab placebo administered subcutaneously (SC)
Q2W or alirocumab 75 mg SC Q2W plus ezetimibe oral placebo daily (Fig. 1). Alirocumab
was administered using a 1-mL autoinjector; patients could self-inject or could designate
another person to assist them if desired. Further details are given in the Supplementary
methods.
Per protocol, patients in the alirocumab arm were to be up-titrated in a blinded
manner to alirocumab 150 mg SC Q2W at week 12 if their week 8 LDL-C value
was ≥100 mg/dL. However, due to an administrative error during the study, an up-
titration threshold of 70 mg/dL instead of 100 mg/dL was utilized. Due to the double-
blinded nature of the protocol, the error was not discovered until the data were analyzed
after the study was complete.
2.3. Endpoints and assessments
The primary endpoint was the percent change from baseline in calculated LDL­C at
24 weeks with alirocumab compared with ezetimibe. Secondary endpoints are listed in
Supplementary Table 2.
Safety was assessed throughout the study by adverse event (AE) reporting, local
tolerability (injection site reactions), laboratory data, vital signs, physical signs, and elec-
trocardiogram. Further details are given in the Supplementary methods. Treatment-
emergent AEs (TEAEs) were defined as AEs that, irrespective of whether considered
drug-related, developed or worsened or became serious during the TEAE period. The
TEAE period was defined as the time from the first dose of study treatment to 70 days
(10 weeks) after last injection, as residual effects of alirocumab were expected up to
10 weeks after last injection.
2.4. Statistical analyses
A sample size of 45 patients per treatment arm was calculated to have 95% power to
detect a mean difference between alirocumab and ezetimibe of 20% in LDL-C percent
change from baseline to week 24 using a 2-sided t-test with 5% significance, assuming a
common standard deviation (SD) of 25% based on a previous alirocumab trial [1] and
with an expected rate of exclusion of 5%. The primary endpoint was assessed in the
intent-to-treat (ITT) population, which included all randomized patients who had at
least one calculated LDL-C value at baseline and at one of the planned time points from
weeks 4 to 24. A pre-specified on-treatment analysis (corresponding to the modified ITT
or mITT) was also carried out which included all randomized and treated patients who
had at least one calculated LDL-C value at baseline and at one of the planned time points
from weeks 4 to 24 on-treatment, defined as the period between the first dose of study
treatment and up to 21 days after last injection or 3 days after last capsule intake, which-
ever came first. Further details are given in the Supplementary methods.
3. Results
3.1. Patients
Of 204 patients screened, 103met the eligibility criteria for the study
and were randomized (52 to the alirocumab arm and 51 to the
ezetimibe arm; Fig. 2). Baseline characteristics and lipid parameters
were generally evenly distributed across the two study arms (Table 1).
A total of four patients were identified as having diabetes mellitus at
screening (three in the alirocumab arm and one in the ezetimibe
arm). Mean baseline LDL-C levels were 141.1 mg/dL (3.65 mmol/L) in
the alirocumab arm and 138.3 mg/dL (3.58 mmol/L) in the ezetimibe
arm (Table 1).
Fig 1. Study design.
Although the protocol called for an LDL-C threshold of ≥100 mg/dL for up-titration, a threshold of ≥70 mg/dL was applied in error in a blinded manner in this study. Arrows along the
bottom of the figure indicate assessment times. EOT = end of treatment; EZE = ezetimibe; LDL-C = low-density lipoprotein cholesterol; NCEP-ATP III, National Cholesterol Education
Program Adult Treatment Panel III; Q2W= every 2 weeks; R = randomization; W= week.
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Fourteen patients in the alirocumab arm were up-titrated in a
blindedmanner atweek 12 to the 150mgQ2Wdosing regimen because
their week 8 LDL-C was ≥70 mg/dL; only one of these patients had
LDL-C N100 mg/dL. Mean baseline LDL-C values were 153.2 mg/dL
(3.96 mmol/L) in patients who were up-titrated to alirocumab
150 mg Q2W and 134.7 mg/dL (3.48 mmol/L) in patients who were not
up-titrated. Baseline values of other lipid values according towhether pa-
tients were up-titrated or not are shown in Supplementary Table 3.
Overall, 44/52 (85%) patients in the alirocumab armand44/51 (86%)
patients in the ezetimibe arm completed the 24-week treatment period
(Fig. 2). The main reason for study treatment discontinuation in both
treatment armswas TEAEs (Fig. 2). Of the 15 patients who prematurely
Fig 2. Patient disposition.
*Life events made continuing too difficult. ITT = intent-to-treat; LDL-C = low-density lipoprotein cholesterol.
Table 1
Baseline characteristics (all randomized patients).
Characteristic (mean [SD] unless otherwise stated) Alirocumab 75 mg Q2W (N = 52) Ezetimibe 10 mg (N = 51)
Age, years 60.8 (4.6) 59.6 (5.3)
Male gender, n (%) 28 (53.8) 27 (52.9)
Race, n (%)
White 46 (88.5) 47 (92.2)
Black or African American 6 (11.5) 4 (7.8)
BMI, kg/m2 30.1 (5.9) 28.4 (6.7)
HbA1c, % 5.7 (0.5) 5.6 (0.4)
Fasting blood glucose, mg/dL 101.4 (14.3) 97.4 (9.0)
Diabetes mellitus, n (%) 3 (5.8) 1 (2.0)
10-Year risk of fatal CVD (SCORE), % 2.97 (1.29) 2.68 (1.14)
Lipid parameters, mg/dL
LDL-C 141.1 (27.1) 138.3 (24.5)
Range (min:max) 77:207 73:186
Apolipoprotein B 104.3 (18.4) 104.3 (19.1)
Total cholesterol 221.7 (33.7) 223.9 (30.2)
Non-HDL-C 167.4 (30.3) 164.0 (29.7)
Lipoprotein (a), median (IQR) 13.0 (4.0:39.0) 16.0 (6.0:34.0)
Triglycerides, median (IQR) 119.0 (89.0:153.0) 117.0 (87.0:154.0)
HDL-C 54.3 (16.1) 59.9 (19.2)
Apolipoprotein A-1 153.1 (29.2) 163.8 (33.4)
There were no clinical or statistically significant between-group differences. To convert glucose measurements to mmol/L, multiply by 0.0555; to convert cholesterol measurements to
mmol/L, multiply by 0.02586; and to convert triglycerides measurements to mmol/L, multiply by 0.01129. BMI = body mass index; CVD = cardiovascular disease; HbA1c = glycated
hemoglobin A1c; HDL­C = high-density lipoprotein cholesterol; IQR = interquartile range; LDL­C = low-density lipoprotein cholesterol; Q2W = every 2 weeks; SCORE = systemic
coronary risk estimation; and SD = standard deviation.
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discontinued treatment, three (6%) patients in the alirocumab arm and
5 (10%) patients in the ezetimibe arm did not have a calculated LDL-C
value at week 24.
Forty-eight patients in each treatment group self-injected for all
injections (92% in the alirocumab arm, 94% in the ezetimibe arm).
Four patients in the alirocumab arm and three in the ezetimibe arm
self-injected for some of the injections and requested another person
to do so for the other injections. No patients asked another person to
perform all their injections.
All randomized patients received at least one dose of their allocated
drug and were included in the ITT and safety populations (Fig. 2). One
patient from each treatment arm withdrew from treatment before any
post-randomization LDL-C measurements were made and so were
excluded from the on-treatment analysis. However, they continued
the study and had LDL-C measurements taken while off-treatment but
before end of the 24-week study period, so they were included in the
ITT analysis.
3.2. Efficacy
For the primary efficacy analysis (ITT analysis), least-squares [LS]
mean (standard error [SE]) percent reductions in LDL-C from baseline
to week 24 were 47 (3)% in the alirocumab group versus 16 (3)% in
the ezetimibe group, with a statistically significant LS mean (SE) differ-
ence between groups of−32 (4)% (p b 0.0001) (Table 2). Results from
the on-treatment analysis were consistent with those from the ITT
analysis: LS mean (SE) LDL-C reductions from baseline to week 24
were 54 (2)% versus 17 (2)% (p b 0.0001), with alirocumab and
ezetimibe, respectively (Table 2).
At week 12, when all patients in the alirocumab arm were receiving
75mgQ2W, LDL-C levelswere reduced by 48 (3)%with alirocumab ver-
sus 20 (3)%with ezetimibe in the ITT analysis, with a between-group LS
mean (SE) difference of−28 (4)% (p b 0.0001). Corresponding LDL-C
reductions in the on-treatment analysis at week 12 were 53 (2)% with
alirocumab versus 20 (2)% with ezetimibe, with a between-group LS
mean (SE) difference of−33 (3)%.
Fig. 3 shows the time-course of changes in LDL-C levels over the
study period for patients treated with alirocumab and ezetimibe. Here
we have shown the on-treatment values since the purpose is to under-
stand the durability of drug effect without any confounding by drop out.
There was a substantial drop in LDL-C from baseline to week 4 in the
patients who received alirocumab, with robust LDL-C reductions main-
tained fromweek 4 to end of the treatment period atweek 24. Statistical
analysis of the interaction between treatment and time point in the
mixed model with repeated measures (see Supplemental methods)
was not significant, suggesting stability of LDL-lowering effect of
alirocumab versus ezetimibe over time (as illustrated in Fig. 3).
The estimated proportions of patients with LDL-C reductions ≥50%
at week 12, before up-titration, were 58% in the alirocumab arm, com-
pared with 3% of patients in the ezetimibe arm (ITT). Corresponding
values in the on-treatment analysis were 65% in the alirocumab arm
and 2% in the ezetimibe arm. All patients responded to alirocumab
while exposed to treatment (on-treatment population) (Supplemental
Fig. 1).
To estimate the impact of the up-titration based on LDL-C≥70 mg/dL
instead of ≥100 mg/dL on the primary efficacy parameter, an additional
analysis was performed excluding LDL-C values post up-titration
for the 13 patients who were up-titrated despite having LDL-C
values b100 mg/dL; this analysis gave results similar to the overall
ITT analysis (Supplementary Table 4).
Percent reductions from baseline in apolipoprotein B, total choles-
terol, and non-high density lipoprotein cholesterol were significantly
greater for alirocumab versus ezetimibe at week 24 and similar in the
ITT and on-treatment analyses (Table 3). Moderate reductions in lipo-
protein (a) [Lp(a)], triglycerides and increases in high-density lipopro-
tein cholesterol were observed following both of the study treatments,
with no significant differences between alirocumab and ezetimibe
arms (Table 3).
Alirocumab efficacy versus ezetimibe was consistent across various
subgroups in the ITT population (Supplementary Fig. 2).
Table 2
Percent change in LDL-C from baseline to week 24 (ITT and on-treatment analysis).
LDL-C Alirocumab 75 mg Q2W Ezetimibe 10 mg Alirocumab versus ezetimibe
LS mean difference (SE) % 95% CI p-Value
ITT N = 52 N = 51
LS mean (SE) change from baseline (%) −47.2 (3.0) −15.6 (3.1) −31.6 (4.3) −40.2 to−23.0 b0.0001a
On-treatmentb N = 51 N = 50
Baseline LDL-C, mean (SD), mg/dL 141.1 (27.4) 137.5 (24.1)
Min:max 77:207 73:186
LS mean (SE) change from baseline (%) −54.1 (2.0) −17.2 (2.0) −36.9 (2.9) −42.7 to−31.2 b0.0001c
CI = confidence intervals; ITT = intent-to-treat; LDL-C = low-density lipoprotein cholesterol; LS = least squares; Q2W = every 2 weeks; SD = standard deviation; and SE = standard
error.
a Statistically significant according to the fixed hierarchical approach used to control overall type-I error rate.
b Includes all patients in the ITT population with at least one calculated LDL-C value at one planned time point between the first dose of study treatment and up to 21 days after last
injection or 3 days after last capsule intake, whichever came first.
c p-Value is shown for descriptive purposes only.
Fig 3. LDL-C levels (mg/dl) versus study time point (on-treatment analysis).
Values aboveweek 12 andweek 24data points indicate LSmean (SE) % change from base-
line. LDL-C = low-density lipoprotein cholesterol; LS = least squares; SE = standard
error.
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3.3. Safety
The overall percentage of patients who experienced at least one
TEAE was 69% in the alirocumab arm and 78% in the ezetimibe arm
(Table 4). There were no deaths. Two serious AEs (SAEs) were reported
during the TEAE period: one patient, who had received alirocumab
75 mg Q2W for 3 months and had a history of atrial fibrillation and
chronic obstructive pulmonary disorder, experienced a pulmonary em-
bolism; study treatmentwas discontinued and the patientwas hospital-
ized, where he recovered. One patient in the ezetimibe arm with a
medical history of arthritis experienced glenoid erosion and was hospi-
talized for surgery (shoulder arthroplasty). The patient recovered in
hospital and completed the study. Neither of the SAEs were considered
by the investigator to be related to the study treatment. TEAEs occurring
in 5% or more patients in either treatment arms are shown in Table 4.
Nine patients prematurely discontinued study treatment following
one or more TEAEs (five [10%] patients in the alirocumab arm and
four [8%] in the ezetimibe arm). In the alirocumab group, TEAEs lead-
ing to discontinuation were pulmonary embolism in one patient,
nausea, fatigue, headache, and flushing in one patient, arthralgia
(generalized aching) in one patient, injection site reaction in one
patient, and diarrhea in one other patient. In the ezetimibe group,
the TEAEs leading to discontinuation were gout in one patient, fa-
tigue, back pain, and frequent urination in one patient, abdominal
cramping and injection site reaction in one patient, and vivid dreams
in one patient.
Muscle-related TEAEs occurred in two (4%) of alirocumab patients
and two (4%) of ezetimibe patients. Elevated creatine kinase levels
over 10 times the upper limit of normal were reported in one patient
in the ezetimibe group (Table 4). Three patients experienced a local in-
jection site reaction (one [2%] patient in the alirocumab group and two
[4%] in the ezetimibe group). These events were of mild intensity. The
patient in the alirocumab arm experienced three episodes of local injec-
tion site reaction following consecutive injections. Three patients who
were treated with alirocumab 75 mg Q2W experienced at least one
LDL-C value b25 mg/dL; no safety concern associated with the low
LDL-C levels was observed with these three patients.
No patients in the alirocumab group and few (two or less) pa-
tients in the ezetimibe group presented abnormalities in vital signs
(blood pressure, heart rate). In addition, there were no increases
over three times the upper limit of normal in alanine aminotransfer-
ase or aspartate aminotransferase (Table 4). More patients had blood
glucose ≥126 mg/dL (7 mmol/L) in the alirocumab arm than in the
ezetimibe arm (six patients vs. one patient; Table 4). However, the six
patients in the alirocumab arm who experienced high blood glucose
during the treatment period had abnormal fasting glucose at screening
or baseline and no pattern was observed in changes in either blood glu-
cose or glycated hemoglobin A1c (HbA1c) from screening to week 24
(Supplementary Table 5).
Treatment emergent anti-drug antibodies were found in six (12%)
patients in the alirocumab arm and were not observed in patients in
the ezetimibe arm. Five of these patientswere classified as having a per-
sistent response with a positive anti-drug antibody status recorded at
follow-up visit. For all anti-drug antibody-positive patients, titers were
low and no neutralizing anti-drug antibody which may impact
alirocumab pharmacokinetics, LDL-C effects, or safety was detected.
4. Discussion
This was the first Phase 3 study of alirocumab and the first to use the
75 mg Q2W dosing regimen. Alirocumab demonstrated superior effica-
cy in monotherapy compared with ezetimibe over 24 weeks of treat-
ment. The reductions in LDL-C observed with alirocumab in this study
suggests that, in thesemoderate CV risk patients whowere not on back-
ground statin therapy, alirocumab 75 mg Q2W is sufficient to provide
N50% LDL-C reduction in most patients. Results of the present study
were generally in linewithwhatwas observed previously in alirocumab
Phase 1 and 2 studies performed with or without background statin
therapy [1–4]. The magnitude of LDL-C lowering of alirocumab mono-
therapy at the starting dose of 75 mg is similar to what can be achieved
with high-intensity statins in monotherapy (50–55% for atorvastatin
80mgor rosuvastatin 40mg daily) [9–11]. In comparison,monotherapy
with evolocumab, another monoclonal antibody to PCSK9, decreased
measured LDL-C by 41–51% with doses 70–140 mg Q2W and by
39–48% with doses 280–420 mg every 4 weeks [12].
In the current study, patientswere up-titrated to alirocumab 150mg
SC Q2W at week 12 if their week 8 LDL-C value was ≥70 mg/dL. While
the alirocumab dose up-titration occurred at a lower LDL-C level than
Table 3
Percent change from baseline in secondary lipid parameters (ITT and on-treatment analysis).
LS mean (SE) % change from baseline to week 24 Alirocumab 75 mg Q2W Ezetimibe 10 mg Alirocumab versus ezetimibe
LS mean difference (SE) % 95% CI p-Value
ITT N = 52 N = 51
Apo B −36.7 (2.3) −11.0 (2.4) −25.8 (3.3) −32.3 to−19.2 b0.0001a
Non-HDL-C −40.6 (2.8) −15.1 (2.9) −25.5 (4.1) −33.5 to−17.4 b0.0001a
Total cholesterol −29.6 (2.1) −10.9 (2.2) −18.7 (3.0) −24.7 to−12.7 b0.0001a
Lp(a)b −16.7 (3.7) −12.3 (3.8) −4.4 (5.3) −14.8 to 5.9 0.4013
TGsb −11.9 (4.2) −10.8 (4.3) −1.2 (5.9) −12.7 to 10.3 0.8433c
HDL-C 6.0 (1.9) 1.6 (1.9) 4.4 (2.7) −1.0 to 9.8 0.1116c
Apo A-1 4.7 (1.6) −0.6 (1.6) 5.3 (2.2) 0.9 to 9.8 0.0196c
On-treatment N = 51 N = 50
Apo B −40.8 (1.9) −11.5 (1.9) −29.2 (2.6) −34.4 to−24.0 b0.0001d
Non-HDL-C −47.1 (1.9) −16.6 (1.9) −30.5 (2.7) −35.9 to−25.1 b0.0001d
Total cholesterol −34.2 (1.6) −12.0 (1.6) −22.2 (2.3) −26.7 to−17.7 b0.0001d
Lp(a)b −17.7 (4.1) −12.3 (4.0) −5.4 (5.7) −16.6 to 5.9 0.3506d
TGsb −14.7 (4.4) −12.7 (4.2) −1.9 (6.0) −13.7 to 9.8 0.7452d
HDL-C 8.0 (1.9) 1.7 (1.9) 6.2 (2.7) 0.8 to 11.6 0.0241d
Apo A-1 5.3 (1.6) −0.7 (1.6) 6.1 (2.3) 1.6 to 10.6 0.0084d
Apo = apolipoprotein; CI = confidence intervals; HDL-C = high-density lipoprotein cholesterol; ITT = intention-to-treat; Lp(a) = lipoprotein (a); LS = least squares; Q2W = every
2 weeks; SE = standard error; and TGs = triglycerides.
a Statistically significant according to the fixed hierarchical approach used to control overall type-I error rate.
b Combined estimate for adjusted mean (SE) percent changes are shown for Lp(a) and TGs.
c As the difference in Lp(a) atweek 24was not significant for alirocumab versus ezetimibe, no further significance testingwasperformed as per thefixedhierarchical approach.p-Values
for TGs, HDL-C and Apo A-1 are shown for descriptive purposes only.
d p-Values are shown for descriptive purposes only.
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planned per protocol (i.e. ≥100 mg/dL), it is not anticipated that the
LDL-lowering efficacy observed would have differed significantly if the
up-titration had been performed at this threshold. In this and prior
studies, the Friedewald method was used to calculate LDL-C concentra-
tions as this is the method routinely used in clinical practice. While it is
understood that calculated LDL-C does not give precise estimates at low
LDL-C levels, only three patients in this study had calculated LDL-C
levels below 25 mg/dL.
The magnitude of decrease in Lp(a) with alirocumab was expected
based on Phase 2 studies where reductions in Lp(a) ranged from
13–35% with the 50–150 mg Q2W dose range [1–3]. The effect of
ezetimibe on Lp(a) is not clear from the literature, with large variations
between studies [13,14].
Alirocumab demonstrated tolerability and safety comparable with
ezetimibe. This is an important observation, as ezetimibe is one of the op-
tions recommended for use in statin intolerant patients due to its
favorable safety profile [6]. Safety results for alirocumab reflected those
of previous Phase 2 trials, where alirocumab was administered on top
of background statin with or without other lipid-lowering therapy [1–3].
To our knowledge, this study was the first blinded, randomized
study to use an autoinjector to administer a monoclonal antibody to
PCSK9, with the autoinjector used to deliver alirocumab doses of both
75 mg and 150 mg in 1 mL SC injections. All patients were able to self-
inject with the autoinjector, with the majority of patients choosing to
self-administer all alirocumab injections.
Thereweremore patients with high blood glucose in the alirocumab
arm than in the ezetimibe arm.However, all had abnormal fasting blood
glucose levels at screening or baseline (based on the American Diabetes
Association definition) [15], with no pattern observed in changes in ei-
ther blood glucose or HbA1c over the course of the study. The number of
patients was too small to draw any firm conclusions. A previous study
reported that male mice over 4 months old with both copies of the
PCSK9 gene deleted, and thus no functional PCSK9 protein, had reduced
insulin levels, increased blood glucose, and glucose intolerance [16].
However, these findings have not been observed in humans with
PCSK9 loss-of-function mutations including those with no functioning
PCSK9 protein [17–19]. One genetic population study suggested that
subjects with both a PCSK9 R46L loss-of-function mutation and an
apoE3/E2 genotype show increased rates of insulin resistance [20]. No
safety concerns related to glucose levels have been reported so far in tri-
als of PCSK9 inhibitors, either with alirocumab [1–3] or evolocumab
[21–23].
The number of patients included in the study was relatively small.
However, the purpose of this study was to provide monotherapy data
Table 4
TEAEs and laboratory parameters (safety population).
AE category or laboratory parameter, n (%) Alirocumab 75 mg Q2W (n = 52) Ezetimibe 10 mg (n = 51)
Patients with any TEAE 36 (69.2) 40 (78.4)
Patients with any treatment emergent SAE 1 (1.9) 1 (2.0)
Patients with any TEAE leading to death 0 0
Patients with any TEAE leading to treatment discontinuation 5 (9.6) 4 (7.8)
TEAEs occurring in ≥5% of patients in either group
Nasopharyngitis 12 (23.1) 8 (15.7)
Diarrhea 6 (11.5) 2 (3.9)
Influenza 6 (11.5) 3 (5.9)
Arthralgia 3 (5.8) 2 (3.9)
Headaches 3 (5.8) 2 (3.9)
Nausea 3 (5.8) 3 (5.9)
Upper respiratory tract infection 2 (3.8) 5 (9.8)
Back paina 1 (1.9) 3 (5.9)
Dizziness 1 (1.9) 3 (5.9)
Urinary tract infection 0 3 (5.9)
Patients with TEAEs of interest
Musculoskeletal and connective tissue disorders 8 (15.4) 11 (21.6)
Muscle disorders 2 (3.8) 2 (3.9)
Myalgia 2 (3.8) 1 (2.0)
Muscle spasms 0 1 (2.0)
Musculoskeletal and connective tissue disorders NEC 2 (3.8) 5 (9.8)
Musculoskeletal pain 1 (1.9) 1 (2.0)
General disorders and administration site conditions 5 (9.6) 5 (9.8)
Injection site reaction 1 (1.9) 2 (3.9)
Laboratory parameters n/N (%)
Alanine aminotransferase (ALT)
≥3× ULN (if baseline ALT b ULN) or ≥2× the baseline value (if baseline ALT ≥ ULN) 0/52 0/51
N3× ULN 0/52 0/51
Aspartate aminotransferase
N3× ULN 0/52 0/51
Glucose
≤70 mg/dL (3.9 mmol/L) and bLLN 0/52 0/50
≥126 mg/dL (7 mmol/L) (fasted) 6/51 (11.8)b 1/50 (2.0)b
Albumin
≤25 g/L 0/51 0/50
Creatine kinase
N3× ULN 0/51 1/50 (2.0)
N10× ULN 0/51 1/50 (2.0)
TEAEs are AEs that developed or worsened or became serious during the TEAE period (defined as the time from the first dose of double-blind study treatment to the last injection plus
70 days [10 weeks], as residual effect of alirocumabwas expected until 10 weeks after last injection). AE = adverse event; LLN = lower limit of normal; NEC = not elsewhere classified;
Q2W = every 2 weeks; SAE = serious adverse event; TEAE = treatment-emergent adverse event; and ULN = upper limit of normal.
a Back pain was also counted as a TEAE of special interest (musculoskeletal and connective tissue disorders NEC).
b The six alirocumab patients and the one ezetimibe patient with blood glucose ≥126 mg/dL (7 mmol/L) had abnormal fasting glucose at screening or baseline (and three of the six
alirocumab patients were identified as having diabetes mellitus at screening); in these patients, no pattern was observed in changes of blood glucose over time (See Supplementary
Table 6).
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to complement the range of data expected to emerge from the ODYSSEY
Phase 3 clinical trial program,which has been designed to further assess
the efficacy and safety of alirocumab, primarily when combined with
statins. The program, comprising 14 studies of more than 23,500 pa-
tients and over 2000 study centers worldwide, will also evaluate
alirocumab as monotherapy in a larger statin intolerant population
(ODYSSEY ALTERNATIVE; NCT01709513), as well as assessing the ef-
fects of alirocumab in addition to statin therapy in a large CV outcomes
trial (ODYSSEY OUTCOMES; NCT01663402).
To summarize, this is thefirst 6-month duration, Phase 3, blinded as-
sessment of the PCSK9 inhibitor alirocumab. A reduction in LDL-C of 48%
was observed in the alirocumab 75 mg Q2W arm at 12 weeks in a
monotherapy population, versus 20% in the ezetimibe arm (ITT analy-
sis). TEAEs occurred in 69.2% of alirocumab patients and 78.4% of
ezetimibe patients. This was also the first randomized, controlled trial
of an injectable monoclonal antibody to PCSK9 utilizing a disposable
autoinjector, which resulted in a low rate of injection-related AEs
(b2% of alirocumab and b4% ezetimibe patients). Alirocumab's superior
efficacy and comparable safetywith ezetimibe suggests it has thepoten-
tial to be useful in clinical settings when an alternative to statin therapy
is needed.
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